Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 3
2005 10
2006 3
2007 4
2008 5
2009 5
2010 8
2011 6
2012 5
2013 5
2014 6
2015 6
2016 14
2017 8
2018 7
2019 18
2020 24
2021 34
2022 26
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. van den Bent MJ, et al. Among authors: herrlinger u. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Hoang-Xuan K, et al. Among authors: herrlinger u. Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Lancet Oncol. 2015. PMID: 26149884 Free article. Review.
Disconnecting multicellular networks in brain tumours.
Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, Winkler F. Venkataramani V, et al. Among authors: herrlinger u. Nat Rev Cancer. 2022 Aug;22(8):481-491. doi: 10.1038/s41568-022-00475-0. Epub 2022 Apr 29. Nat Rev Cancer. 2022. PMID: 35488036 Review.
Gliomatosis cerebri.
Herrlinger U. Herrlinger U. Handb Clin Neurol. 2012;105:507-15. doi: 10.1016/B978-0-444-53502-3.00005-7. Handb Clin Neurol. 2012. PMID: 22230515 Review. No abstract available.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. van den Bent MJ, et al. Among authors: herrlinger u. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Lancet. 2017. PMID: 28801186 Free PMC article.
News on the horizon in glioblastoma therapy.
Herrlinger U. Herrlinger U. ESMO Open. 2020 Feb;5(1):e000601. doi: 10.1136/esmoopen-2019-000601. ESMO Open. 2020. PMID: 32054632 Free PMC article.
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N, Poschke I, Lindner K, Bunse L, Mildenberger I, Boschert T, Jähne K, Green EW, Hülsmeyer I, Jünger S, Kessler T, Suwala AK, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Sahm F, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M, Sahm K. Grassl N, et al. Among authors: herrlinger u. Nat Med. 2023 Oct;29(10):2586-2592. doi: 10.1038/s41591-023-02555-6. Epub 2023 Sep 21. Nat Med. 2023. PMID: 37735561 Free PMC article.
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
Drexler R, Göttsche J, Sauvigny T, Schüller U, Khatri R, Hausmann F, Hänzelmann S, Huber TB, Bonn S, Heiland DH, Delev D, Venkataramani V, Winkler F, Weller J, Zeyen T, Herrlinger U, Gempt J, Ricklefs FL, Dührsen L. Drexler R, et al. Among authors: herrlinger u. Neuro Oncol. 2023 May 4;25(5):1006-1008. doi: 10.1093/neuonc/noad014. Neuro Oncol. 2023. PMID: 36860191 Free PMC article. No abstract available.
Prognostic factors in leptomeningeal metastases.
Le Rhun E, Devos P, Weller J, Seystahl K, Mo F, Compter A, Berghoff AS, Jongen JLM, Wolpert F, Rudà R, Brandsma D, van den Bent M, Preusser M, Herrlinger U, Weller M. Le Rhun E, et al. Among authors: herrlinger u. Neuro Oncol. 2021 Jul 1;23(7):1208-1209. doi: 10.1093/neuonc/noab051. Neuro Oncol. 2021. PMID: 33830220 Free PMC article. No abstract available.
202 results